PDF(Pubmed)
Abstract：
OBJECTIVE: Tendinopathy is a common condition that affects the body\'s tendon structures, causing discomfort, restricted movement, and reduced functionality. In this study, we looked at how extracorporeal shock wave therapy (ESWT) affected pain levels in individuals with various forms of tendinopathy around the world.
METHODS: This study is a comprehensive review and meta-analysis of previously published randomized controlled trials. To gather relevant data, the researchers performed keyword searches in international databases, including PubMed (Medline), Scopus, Web of Sciences, Cochrane Central Register of Controlled Trials (CENTRAL), Research Registers of ongoing trials (ClinicalTrials.gov), as well as Embase. The search was conducted up until March 2023. The quality of the selected articles was assessed using the Cochrane risk-of-bias method for randomized trials (RoB2).
RESULTS: Based on the results of the meta-analysis, which included 45 clinical studies, the use of ESWT was found to have a significant impact on reducing pain in various conditions. The standardized mean difference (SMD) in patients with plantar fasciitis (PF) was reduced by 1.63 (SMD: -1.63, 95% CI: -3.04, -0.21; I2: 77.36%; P heterogeneity: 0.0001). For lateral epicondylitis (LE), the SMD was 0.63 (SMD: -0.63, 95% CI: -1.11, -0.16; I2: 67.50%; P heterogeneity: 0.003). In the case of chronic Achilles tendinopathy, the SMD was 1.38 (SMD: -1.38, 95% CI: -1.66, -1.10; I2: 96.44%; P heterogeneity: 0.0001). Additionally, in individuals with rotator cuff tendinopathy, the SMD for pain reduction was 2.37 units (SMD: -2.37, 95% CI: -3.58, -1.15; I2: 98.46%; P heterogeneity: 0.0001).
CONCLUSIONS: This study suggests that ESWT can be a highly effective therapy option for relieving pain in people with tendinopathy. Nonetheless, it is encouraged to make additional recommendations based on high-quality clinical research and more accurate information in order to define the optimal therapeutic options for each type of tendinopathy.
METHODS: This study is a comprehensive review and meta-analysis of previously published randomized controlled trials. To gather relevant data, the researchers performed keyword searches in international databases, including PubMed (Medline), Scopus, Web of Sciences, Cochrane Central Register of Controlled Trials (CENTRAL), Research Registers of ongoing trials (ClinicalTrials.gov), as well as Embase. The search was conducted up until March 2023. The quality of the selected articles was assessed using the Cochrane risk-of-bias method for randomized trials (RoB2).
RESULTS: Based on the results of the meta-analysis, which included 45 clinical studies, the use of ESWT was found to have a significant impact on reducing pain in various conditions. The standardized mean difference (SMD) in patients with plantar fasciitis (PF) was reduced by 1.63 (SMD: -1.63, 95% CI: -3.04, -0.21; I2: 77.36%; P heterogeneity: 0.0001). For lateral epicondylitis (LE), the SMD was 0.63 (SMD: -0.63, 95% CI: -1.11, -0.16; I2: 67.50%; P heterogeneity: 0.003). In the case of chronic Achilles tendinopathy, the SMD was 1.38 (SMD: -1.38, 95% CI: -1.66, -1.10; I2: 96.44%; P heterogeneity: 0.0001). Additionally, in individuals with rotator cuff tendinopathy, the SMD for pain reduction was 2.37 units (SMD: -2.37, 95% CI: -3.58, -1.15; I2: 98.46%; P heterogeneity: 0.0001).
CONCLUSIONS: This study suggests that ESWT can be a highly effective therapy option for relieving pain in people with tendinopathy. Nonetheless, it is encouraged to make additional recommendations based on high-quality clinical research and more accurate information in order to define the optimal therapeutic options for each type of tendinopathy.
摘要：
目的：肌腱病是影响人体肌腱结构的常见病，引起不适，限制移动,减少功能。在这项研究中,我们研究了体外冲击波疗法(ESWT)如何影响世界各地患有各种形式肌腱病的个体的疼痛水平.
方法：本研究是对以前发表的随机对照试验的综合综述和荟萃分析。为了收集相关数据，研究人员在国际数据库中进行了关键词搜索，包括PubMed(Medline)，Scopus,WebofSciences,Cochrane中央对照试验登记册（中央），正在进行的试验的研究登记册(ClinicalTrials.gov)，以及Embase。搜索一直持续到2023年3月。所选文章的质量使用Cochrane偏倚风险方法进行随机试验（RoB2）评估。
结果：根据荟萃分析的结果，其中包括45项临床研究，发现使用ESWT对减轻各种情况下的疼痛有显著影响.足底筋膜炎（PF）患者的标准化平均差异（SMD）降低了1.63（SMD：-1.63，95％CI：-3.04，-0.21；I2：77.36％；P异质性：0.0001）。对于外侧上髁炎（LE），SMD为0.63(SMD:-0.63,95%CI:-1.11,-0.16;I2:67.50%;P异质性:0.003)。在慢性跟腱病的情况下，SMD为1.38(SMD:-1.38,95%CI:-1.66,-1.10;I2:96.44%;P异质性:0.0001)。此外,在患有肩袖肌腱病的个体中，减轻疼痛的SMD为2.37个单位(SMD:-2.37,95%CI:-3.58,-1.15;I2:98.46%;P异质性:0.0001).
结论：这项研究表明，ESWT可以成为缓解肌腱病患者疼痛的高效治疗选择。尽管如此，我们鼓励根据高质量的临床研究和更准确的信息提出额外的建议,以确定每种肌腱病的最佳治疗方案.
方法：本研究是对以前发表的随机对照试验的综合综述和荟萃分析。为了收集相关数据，研究人员在国际数据库中进行了关键词搜索，包括PubMed(Medline)，Scopus,WebofSciences,Cochrane中央对照试验登记册（中央），正在进行的试验的研究登记册(ClinicalTrials.gov)，以及Embase。搜索一直持续到2023年3月。所选文章的质量使用Cochrane偏倚风险方法进行随机试验（RoB2）评估。
结果：根据荟萃分析的结果，其中包括45项临床研究，发现使用ESWT对减轻各种情况下的疼痛有显著影响.足底筋膜炎（PF）患者的标准化平均差异（SMD）降低了1.63（SMD：-1.63，95％CI：-3.04，-0.21；I2：77.36％；P异质性：0.0001）。对于外侧上髁炎（LE），SMD为0.63(SMD:-0.63,95%CI:-1.11,-0.16;I2:67.50%;P异质性:0.003)。在慢性跟腱病的情况下，SMD为1.38(SMD:-1.38,95%CI:-1.66,-1.10;I2:96.44%;P异质性:0.0001)。此外,在患有肩袖肌腱病的个体中，减轻疼痛的SMD为2.37个单位(SMD:-2.37,95%CI:-3.58,-1.15;I2:98.46%;P异质性:0.0001).
结论：这项研究表明，ESWT可以成为缓解肌腱病患者疼痛的高效治疗选择。尽管如此，我们鼓励根据高质量的临床研究和更准确的信息提出额外的建议,以确定每种肌腱病的最佳治疗方案.
